BARDA has purchased anthrax antitoxin from Elusys Therapeutics Inc., for the Strategic National Stockpile as part of an integrated, portfolio approach to protecting Americans from 21st century health security threats. This antitoxin can be used in conjunction with antibiotics to help protect Americans in the event of anthrax exposure. It was purchased using funding from Project BioShield, which funds the late-stage development and procurement of critical medical countermeasures.
BARDA has issued Requests for Information (RFIs) for transformative tools and technologies related to sepsis and for early detection and diagnosis of chemical and biological exposures and infections. If your organization is developing these capabilities, let us know by responding to these RFIs.
El gobernador McKee presenta una enmienda presupuestaria de $1,3 millones para apoyar a las empresas afectadas por el puente de Washington PROVIDENCE,...
30,000 in RI Applied for 2,500 Charter School Seats Tens of thousands of students are seeking to attend Rhode Island’s public charter schools. There...
